Immuno Oncology
The Science of Surviving Cancer & Thriving After
Unlike chemotherapy, radiation, or surgery, immunotherapy trains the body to recognize and destroy cancer cells, while preserving healthy tissue.
Why Immunotherapy?
At Agenus, we’re advancing the next frontier of immuno-oncology (IO) treatments designed to deliver deeper, more durable responses and to help patients live fuller lives beyond cancer treatment.
IO can attack cancer at the cellular level. By training immune memory, it enhances the body’s ability to keep cancer at bay long after treatment ends.
IO therapies preserve healthy cells more effectively than chemotherapy, surgery, or radiation—traditional treatments that can sometimes lead to long-term side effects or permanent disability.
Our Approach
Aligning Development with the Immune Cycle
The immune system works in cycles recognizing threats, activating defenses and restoring balance. Agenus’ development pipeline is designed to modulate this cycle, reawakening suppressed immune responses that cancer has silenced.
Tumors can hide in plain sight. Agenus therapies are built to unmask hidden tumors and train the immune system to mount a precise, sustained attack.
Agenus agents work in concert to keep immune cells engaged long enough to eradicate cancer and build lasting immune memory that can guard against relapse.
Phase 3 → Trial of BOT + BAL
Botensilimab (Fc-enhanced anti-CTLA-4) plus Balstilimab (PD-1 inhibitor) is a next generation immunotherapy combination currently enrolling the phase 3 BATTMAN trial for microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Pushing the Frontiers Of Immuno-Oncology
For 30 years, Agenus has advanced pioneering science that has shaped the field of immuno-oncology.
